Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity

IF 5.7 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2023-12-18 DOI:10.1007/s11883-023-01180-5

Krunal Amin, Garrett Bethel, Larry R. Jackson, Utibe R. Essien, Caroline E. Sloan

{"title":"Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity","authors":"Krunal Amin, Garrett Bethel, Larry R. Jackson, Utibe R. Essien, Caroline E. Sloan","doi":"10.1007/s11883-023-01180-5","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Pharmacoequity refers to the goal of ensuring that all patients have access to high-quality medications, regardless of their race, ethnicity, gender, or other characteristics. The goal of this article is to review current evidence on disparities in access to cardiovascular drug therapies across sociodemographic subgroups, with a focus on heart failure, atrial fibrillation, and dyslipidemia.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Considerable and consistent disparities to life-prolonging heart failure, atrial fibrillation, and dyslipidemia medications exist in clinical trial representation, access to specialist care, prescription of guideline-based therapy, drug affordability, and pharmacy accessibility across racial, ethnic, gender, and other sociodemographic subgroups.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Researchers, health systems, and policy makers can take steps to improve pharmacoequity by diversifying clinical trial enrollment, increasing access to inpatient and outpatient cardiology care, nudging clinicians to increase prescription of guideline-directed medical therapy, and pursuing system-level reforms to improve drug access and affordability.</p>","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"1 1","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-023-01180-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

Pharmacoequity refers to the goal of ensuring that all patients have access to high-quality medications, regardless of their race, ethnicity, gender, or other characteristics. The goal of this article is to review current evidence on disparities in access to cardiovascular drug therapies across sociodemographic subgroups, with a focus on heart failure, atrial fibrillation, and dyslipidemia.

Recent Findings

Considerable and consistent disparities to life-prolonging heart failure, atrial fibrillation, and dyslipidemia medications exist in clinical trial representation, access to specialist care, prescription of guideline-based therapy, drug affordability, and pharmacy accessibility across racial, ethnic, gender, and other sociodemographic subgroups.

Summary

Researchers, health systems, and policy makers can take steps to improve pharmacoequity by diversifying clinical trial enrollment, increasing access to inpatient and outpatient cardiology care, nudging clinicians to increase prescription of guideline-directed medical therapy, and pursuing system-level reforms to improve drug access and affordability.

Abstract Image

查看原文本刊更多论文

消除心房颤动、心力衰竭和血脂异常的健康差异：实现药物公平之路

综述目的公平用药是指确保所有患者都能获得高质量药物治疗的目标，无论其种族、民族、性别或其他特征如何。本文旨在回顾目前不同社会人口亚群在获得心血管药物治疗方面存在差异的证据，重点关注心力衰竭、心房颤动和血脂异常。最新研究结果不同种族、民族、性别和其他社会人口亚群在临床试验代表性、获得专科护理的机会、基于指南的治疗处方、药物可负担性和药房可及性等方面，在获得延长生命的心衰、心房颤动和血脂异常药物治疗方面存在相当大且一致的差距。小结研究人员、医疗系统和政策制定者可以采取以下措施来改善药物公平性：实现临床试验注册的多样化；增加住院和门诊心脏病治疗的可及性；鼓励临床医生增加以指南为指导的医疗处方；进行系统层面的改革以改善药物的可及性和可负担性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.